ArticleMolecular neurobiology2026
Ptbp2 Alleviates Neuroinflammation and Blood-brain Barrier Disruption via Modulating Microglial Polarization in Ischemic Stroke.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Resveratrol as a potential natural compound to ameliorate cognitive impairment in aluminum-exposed mice: impacts on behavior, purinergic system, and brain inflammation.Metabolic brain disease · 2026Article
- Sodium oligomannate reduces cerebral infarction and improves neurological function through microbiota remodeling in MCAO/R rats.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Damage following ischemic stroke is worsened by microglial activation and subsequent neuroinflammation. Polypyrimidine tract binding protein 2 (Ptbp2) can influence the chemotaxis and repolarization of cancer-related macrophages; however, its specific role in microglial polarization and the underlying mechanisms are not yet fully understood. This study aimed to elucidate the neuroprotective mechanisms of Ptbp2 and examine its effects on microglial activation, neuroinflammation, and glucose metabolism following cerebral ischemia. Mice model of ischemic stroke was developed using temporary middle cerebral artery occlusion (tMCAO). Adeno-associated viruses were used for overexpression and knockdown in C57 mice, and microglial polarization, blood-brain barrier (BBB) integrity, and glycolytic parameters in the peri-infarct cortex were evaluated. RNA sequencing (RNA-seq) was performed on mouse brain tissues. To investigate the underlying mechanisms, the mouse brain microvascular endothelial cell line bEnd.3 and BV2 microglial cell line were used. The protective effect of Ptbp2 on BBB integrity following stroke was evaluated by targeted overexpression and knockdown. We found that Ptbp2 overexpression reduced microglia-mediated neuroinflammation and BBB damage while inhibiting pathological glycolysis, according to findings from both in vitro and in vivo studies. Additionally, Ptbp2 level was significantly downregulated in patients with stroke compared to controls, and was inversely correlated with the severity of neural impairment. Our study unveils novel immunomodulatory mechanisms in stroke and highlights Ptbp2 and its regulatory network as potential therapeutic targets for stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.